Yıl: 2021 Cilt: 1 Sayı: 37 Sayfa Aralığı: 49 - 58 Metin Dili: İngilizce DOI: 10.47717/turkjsurg.2020.4931 İndeks Tarihi: 13-05-2022

D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer

Öz:
Objective: Gastric cancer is a common malignancy worldwide. Effective treatment by interdisciplinary cooperation is important, and surgery still plays an important role. Material and Methods: In a ten-year period, 355 patients were diagnosed to have gastric cancer. One hundred and sixty-two patients with a median (range) age of 58 (23-83) years were eligible for the study. There were 107 patients in D2 and 55 patients in D2 lymphadenectomy plus para-aortic lymph node (PALN) dissection group. The two groups were compared in terms of complications, morbidity, mortality and long-term survival. Results: Length of stay was 12 (8-34) days for D2 and 14 (8-42) days for D2 plus PALND. Total number of operative mortality was 8/162 (5%), and it was not different between the groups. Twenty patients (18%) had complications in D2 group and 9 (17%) patients in D2 plus PALND group. Overall survival was also similar between the groups, but patients with T3-T4 tumors, patients with stage IIIA and IIIB disease had better survival with D2 plus PALN dissection. We found that the depth of invasion, PLN, ratio (PLN/TLN), stage and LND were all prognostic variables. Conclusion: This study showed that D2 plus PALN dissection for advanced gastric cancer can be performed as safely as a standard D2 dissection by experienced surgeons without increasing postoperative morbidity and mortality. D2 plus PALN dissection should be preferred in the advanced stage of the disease (IIIA-IIIB) as it increases the rate of survival.
Anahtar Kelime:

İleri evre mide kanserlerinde D2 ve D2+ para-aortik lenf nodu diseksiyonu sonuçlarının karşılaştırılması

Öz:
Giriş ve Amaç: Mide kanseri dünya çapında yaygın bir malignitedir. Disiplinler arası işbirliği ile etkili tedavi önemlidir ve cerrahi hala önemli bir rol oynamaktadır. Gereç ve Yöntem: Kliniğimizde on yıl içinde 355 hastaya mide kanseri teşhisi kondu. Medyan yaşı 58 (23-83) olan 162 hasta çalışmaya uygundu. D2’de 107 hasta ve D2 lenfadenektomi artı para-aortik lenf nodu (PALN) diseksiyon grubunda 55 hasta vardı. İki grup komplikasyon, morbidite, mortalite ve uzun süreli sağkalım açısından karşılaştırıldı. Bulgular: Hastanede kalış süresi D2 için 12 (8-34) gün ve D2+ PALND için 14 (8-42) gündü. Toplam operatif mortalite sayısı 8/162 (%5) idi ve gruplar arasında farklı değildi. 20 hastada (%18) D2 grubunda komplikasyon, 9 hastada (%17) D2+ PALND grubunda komplikasyon vardı. Genel sağkalım gruplar arasında da benzerdi, ancak T3-T4 tümörleri olan hastalar, evre IIIA ve IIIB hastalığı olan hastalar ve daha yüksek PLN/TLN oranı olan hastalar D2+ PALN diseksiyonu ile daha iyi sağkalım gösterdi. İnvazyon derinliği, PLN, PLN/TLN oranı, evre ve LND’nun bağımsız prognostik değişkenler olduğunu bulduk. Sonuç: Bu çalışma, D2+ PALN diseksiyonunun ileri evre mide kanseri için, postoperatif morbidite ve mortaliteyi arttırmadan deneyimli cerrahlar tarafından standart bir D2 diseksiyonu kadar güvenli bir şekilde yapılabileceğini göstermiştir. D2+ PALN diseksiyonu, sağkalım oranını arttırdığı için hastalığın ileri evresinde (IIIA-IIIB) tercih edilmelidir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Takagane A, Terashima M, Abe K, Araya M, Irinoda T, Yonezawa H, et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 1999; 2: 122-8. [CrossRef]
  • 2. Shimoyama S, Kaminishi M, Joujima Y, Oohara T, Hamada C, Teshigawara W. Lymph node involvement correlation with survival in advanced gastric carcinoma: univariate and multivariate analyses. J Surg Oncol 1994; 57: 164-70. [CrossRef]
  • 3. Kunisaki C, Shimada H, Yamaoka H, Wagasugi J, Takahashi M, Akiyama H, et al. Significance of para-aortic lymph node dissection in advanced gastric cancer. Hepatogastroenterology 1999; 46: 2635-42. [CrossRef]
  • 4. Mishima Y, Hirayama R. The role of lymph node surgery in gastric cancer. World J Surg 1987; 11: 406-11. [CrossRef]
  • 5. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11: 418- 25. [CrossRef]
  • 6. Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999; 125: 325-31. [CrossRef]
  • 7. Maehara Y, Kakeji Y, Koga T, Emi Y, Baba H, Akazawa K, et al. Therapeutic value of lymph node dissection and the clinical outcome for patients with gastric cancer. Surgery 2002; 131: 85-91. [CrossRef]
  • 8. McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg 2005; 92: 5-13. [CrossRef]
  • 9. Kasakura Y, Mochizuki F, Wakabayashi K, Kochi M, Fujii M, Takayama T. An evaluation of the effectiveness of extended lymph node dissection in patients with advanced gastric cancer: a retrospective study of 1403 cases at a single institution. J Surg Res 2002; 103: 252-9. [CrossRef]
  • 10. Adachi Y, Kitano S, Sugimachi K. Surgery for gastric cancer: 10-year experience worldwide. Gastric Cancer 2001; 4: 166-74. [CrossRef]
  • 11. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomized comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 748-58. [CrossRef]
  • 12. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer:preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347: 995-99. [CrossRef]
  • 13. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-61. [CrossRef]
  • 14. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004; 90: 1727-32. [CrossRef]
  • 15. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998; 123: 573-8. [CrossRef]
  • 16. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomized surgical trial. Eur J Surg Oncol 2004; 30: 303-8. [CrossRef]
  • 17. Hartgrink HH, van de Velde CJH, Putter H, Bonenkamp JJ, Klein KE, Songun I,et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004; 22: 2069-77. [CrossRef]
  • 18. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJH, Welvaart K, Songun I, et al. Extended lymph node dissection for gastric cancer. N Engl J Med 1999; 340: 908-14. [CrossRef]
  • 19. Kajitani T. The general rules of gastric cancer study in surgery and pathology: Part 1-clinical classification. Jpn J Surg 1981; 11: 127-39. [CrossRef]
  • 20. Sano T, Sasako M, Yamamoto S, Hashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004; 22: 2767-73. [CrossRef]
  • 21. Baba H, Hokita S, Natsugoe S, Miyazono T, Shimada M, Nakano S. Paraaortic lympadenectomy in patients with advanced gastric carcinoma of the upper-third of the stomach. Hepatogastroenterology 2000; 47: 893-6. [CrossRef]
  • 22. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 1996; 23: 360-8. [CrossRef]
  • 23. Sasagawa T, Solano H, Vega W, Mena F. The effectiveness of extended lymph node dissection for gastric cancer performed in Costa Rica under supervision of a Japanese surgeon: a comparison with surgical results in Japan. Am J Surg 2008; 195: 53-60. [CrossRef]
  • 24. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75: 110-2. [CrossRef]
  • 25. Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001; 84: 1602-9. [CrossRef]
  • 26. Roviello F, Marrelli D, Morgagni P, on behalf of the Italian Research Group for Gastric Cancer. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. An Surg Oncol 2002; 9: 894- 900. [CrossRef]
  • 27. Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A, on behalf of the Gastric Cancer Study Group of Japan Clinical Oncology Group. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005; 92: 1103-9. [CrossRef]
  • 28. Kunisaki C, Shimada H, Yamaoka H, Takahashi M, Ookubo K, Akiyama H. Indications for paraaortic lymph node dissection in gastric cancer patients with paraaortic lymph node involvement. Hepatogastroenterology 2000; 47: 586-9. [CrossRef]
  • 29. Isozaki H, Okajima K, Fujii K, Nomura E, Izumi M, Mabuchi H. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 1999; 46: 549-54. [CrossRef]
  • 30. Yonemura Y, Katayama K, Kamata T, Fushida S, Segawa M, Ooyama S. Surgical treatment of advanced gastric cancer with metastasis in para-aortic lymph node. Int Surg 1991; 76: 222-5. [CrossRef]
  • 31. Kitamura M, Arai K, Iwasaki Y. Clinico-pathological studies on para- aortic lymph node metastasis and postoperative quality of life in gastric cancer patients. Jpn J Gastroenterol Surg 1995; 28: 923-6. [CrossRef]
  • 32. Marrelli D, Pedrazzani C, Neri A, Corso G, DeStefano A, Pinto E, et al. Complications after extended (D2) and superextended (D3) lymphadenectomy for gastric cancer: analysis of potential risk factors. Ann Surg Oncol 2007; 14(1): 25-33. [CrossRef]
  • 33. Gunther K, Horbach T, Merkel S, Meyer M, Schnell U, Klein P, Hohenberger W. D3 lymph node dissection in gastric cancer: evaluation of postoperative mortality and complications. Surg Today 2000; 30: 700- 5. [CrossRef]
  • 34. Bostanci EB, Kayaalp C, Ozogul Y, Aydin C, Atalay F, Akoglu M. Comparison of complications after D2 and D3 dissection for gastric cancer. Eur J Surg Oncol 2004; 30: 20-25. [CrossRef]
  • 35. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2020; 10.1007/ s10120-020-01042-y. [CrossRef]
  • 36. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. England J Med 2008; 359(5): 453-62. [CrossRef]
  • 37. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, et al. Selecting a spesific pre- or postoperative adjuvant theraphy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6: 931-9. [CrossRef]
  • 38. Liakakos T, Roukos DH. More controversy than ever: challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008; 15(4): 956-60. [CrossRef]
  • 39. Ozmen MM, Zulfikaroglu B, Kucuk NO, Ozalp N, Aras G, Koseoglu T, et al. Lymphoscintigraphy in detection of the regional lymph node involvement in gastric cancer. Ann R Coll Surg Engl 2006; 88(7): 632-8. [CrossRef]
  • 40. Ozmen MM, Ozmen F, Zulfikaroglu B. Lymph nodes in gastric cancer. J Surg Oncol 2008; 98(6): 476-81. [CrossRef]
  • 41. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A, on behalf of the Polish Gastric Cancer Study Group. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007; 193: 10-5. [CrossRef]
  • 42. Danielson H, Kokkola A, Kiviluoto T, Siren J, Louhimo J, Kivilaakso E, et al. Clinical outcome after D1 vs D2-3 gastrectomy for treatment of gastric cancer. Scand J Surg 2007; 96: 35-40. [CrossRef]
  • 43. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, et al. Comparison of surgical results of D2 vs D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. Ann Surg Oncol 2006; 13(5): 659-67. [CrossRef]
  • 44. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2: 98-107. [CrossRef]
  • 45. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer 1999; 79: 1522-30. [CrossRef]
  • 46. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004; 91: 283-7. [CrossRef]
  • 47. Kiyokawa T, Fukagawa T. Recent trends from the results of clinical trials on gastric cancer surgery. Cancer Communications 2019; 39(1): 11. [CrossRef]
  • 48. Zhang YX, Yang K. Significance of nodal dissection and nodal positivity in gastric cancer. Translational Gastroenterology and Hepatology 2020; 5. [CrossRef]
  • 49. Bencivenga M, Verlato G, Mengardo V, Scorsone L, Sacco M, Torroni L, et al. Is There Any Role for Super-Extended Limphadenectomy in Advanced Gastric Cancer? Results of an Observational Study from a Western High Volume Center. Journal of clinical medicine 2019; 8(11); 1799. [CrossRef]
  • 50. Liang H, Deng J. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. Chinese Journal of Cancer Research 2016; 28(4); 397. [CrossRef]
  • 51. Dong YP, Deng JY. Advances in para-aortic nodal dissection in gastric cancer surgery: A review of research progress over the last decade. World J Clin Cases 2020; 8(13): 2703. [CrossRef]
  • 52. Persiani R, Rausei S, Biondi A, Boccia S, Cananzi F, D’Ugo D. Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer. Eur J Surg Oncol 2008; 34(5): 519-24. [CrossRef]
  • 53. Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 1(94): 2862-6. [CrossRef]
  • 54. Inoue K, Nakane Y, Iiyama H, Sato M, Kanbara T, Nakai K, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9: 27-34. [CrossRef]
  • 55. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007; 14(2): 317-28. [CrossRef]
  • 56. Shen JY, Kim S, Cheong JH, Kim YI, Hyung WJ, Choi WH, et al. The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancer. Cancer 2007; 110(4): 745-51. [CrossRef]
  • 57. Verlato G, Marrelli D, Accordini S, Bencivenga M, Di Leo A, Marchet A, Petrioli R, Zoppini G, Muggeo M, Roviello F, de Manzoni G. Short-term and long-term risk factors in gastric cancer. World J Gastroenterol 2015 ; 21(21): 6434-43. [CrossRef]
  • 58. de Manzoni G, Verlato G, Bencivenga M, Marrelli D, Di Leo A, Giacopuzzi S, Cipollari C, Roviello F. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol 2015; 41(4): 534-40. [CrossRef]
APA ozmen m, Zulfikaroglu B, ozmen f, Moran M, Özalp n, Seçkin S (2021). D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. , 49 - 58. 10.47717/turkjsurg.2020.4931
Chicago ozmen mehmet mahir,Zulfikaroglu Baris,ozmen fusun,Moran Münevver,Özalp nejdet,Seçkin Selda D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. (2021): 49 - 58. 10.47717/turkjsurg.2020.4931
MLA ozmen mehmet mahir,Zulfikaroglu Baris,ozmen fusun,Moran Münevver,Özalp nejdet,Seçkin Selda D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. , 2021, ss.49 - 58. 10.47717/turkjsurg.2020.4931
AMA ozmen m,Zulfikaroglu B,ozmen f,Moran M,Özalp n,Seçkin S D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. . 2021; 49 - 58. 10.47717/turkjsurg.2020.4931
Vancouver ozmen m,Zulfikaroglu B,ozmen f,Moran M,Özalp n,Seçkin S D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. . 2021; 49 - 58. 10.47717/turkjsurg.2020.4931
IEEE ozmen m,Zulfikaroglu B,ozmen f,Moran M,Özalp n,Seçkin S "D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer." , ss.49 - 58, 2021. 10.47717/turkjsurg.2020.4931
ISNAD ozmen, mehmet mahir vd. "D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer". (2021), 49-58. https://doi.org/10.47717/turkjsurg.2020.4931
APA ozmen m, Zulfikaroglu B, ozmen f, Moran M, Özalp n, Seçkin S (2021). D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. Turkish Journal of Surgery, 1(37), 49 - 58. 10.47717/turkjsurg.2020.4931
Chicago ozmen mehmet mahir,Zulfikaroglu Baris,ozmen fusun,Moran Münevver,Özalp nejdet,Seçkin Selda D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. Turkish Journal of Surgery 1, no.37 (2021): 49 - 58. 10.47717/turkjsurg.2020.4931
MLA ozmen mehmet mahir,Zulfikaroglu Baris,ozmen fusun,Moran Münevver,Özalp nejdet,Seçkin Selda D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. Turkish Journal of Surgery, vol.1, no.37, 2021, ss.49 - 58. 10.47717/turkjsurg.2020.4931
AMA ozmen m,Zulfikaroglu B,ozmen f,Moran M,Özalp n,Seçkin S D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. Turkish Journal of Surgery. 2021; 1(37): 49 - 58. 10.47717/turkjsurg.2020.4931
Vancouver ozmen m,Zulfikaroglu B,ozmen f,Moran M,Özalp n,Seçkin S D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. Turkish Journal of Surgery. 2021; 1(37): 49 - 58. 10.47717/turkjsurg.2020.4931
IEEE ozmen m,Zulfikaroglu B,ozmen f,Moran M,Özalp n,Seçkin S "D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer." Turkish Journal of Surgery, 1, ss.49 - 58, 2021. 10.47717/turkjsurg.2020.4931
ISNAD ozmen, mehmet mahir vd. "D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer". Turkish Journal of Surgery 1/37 (2021), 49-58. https://doi.org/10.47717/turkjsurg.2020.4931